Central Nervous System News and Research

RSS

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.

22 Jul 2010

Euthymics Bioscience completes $24 million Series A financing

Euthymics Bioscience, Inc., a clinical-stage company developing next-generation antidepressants, today announced the completion of a Series A financing -- led by Novartis Venture Funds and Venture Investors - for a total investment commitment of $24 million in milestone-conditioned tranches. Hambrecht & Quist Capital Management, LLC, GBS Venture Partners and the State of Wisconsin Investment Board also participated in the financing.

22 Jul 2010

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.

22 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

Cara Therapeutics closes Series D financing of $15 million

Cara Therapeutics, Inc. announced today that it had closed on a Series D financing of $15 million. The round was led by new investor, Rho Ventures, with participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equity, Mitsubishi International Corporation and MVM Life Science Partners.

21 Jul 2010

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Acorda Therapeutics, Inc. today announced the National Heart, Lung, and Blood Institute has awarded a $1 million Cardiac Translational Research Implementation Program grant to support research on Glial Growth Factor 2, a novel investigational agent for the treatment of patients with heart failure under development at Acorda.

20 Jul 2010

Bi-monthly journal on neurovirology from Springer

Starting in January 2011, Springer will publish the Journal of NeuroVirology, a bi-monthly publication closely affiliated with the International Society for NeuroVirology. Previously published by Taylor & Francis/Informa, the five-year contract with Springer runs to 2015.

20 Jul 2010

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

Cryo-Cell second-quarter consolidated revenues decrease to $4.3 million

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks, today announced results for the second quarter ended May 31, 2010. Consolidated revenues for the second quarter of fiscal 2010 were $4.3 million compared to $4.7 million for the second quarter of fiscal 2009.

15 Jul 2010

Scientists awarded $2.3M grant to develop new treatments for drug addiction

A pair of scientists on the Florida campus of The Scripps Research Institute has been awarded a $2.3 million grant by the National Institutes of Health to conduct research relevant to developing new treatments for drug addiction.

15 Jul 2010

AD may lead to increased risk of comorbid conditions, research shows

Pfizer Inc., together with its collaborator on the Alzheimer's Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 from two podium and four poster presentations.

14 Jul 2010

CSHL scientists reverse symptoms of Type III SMA using ASOs

The devastating, currently incurable motor-neuron disease spinal muscular atrophy might soon be treated with tiny, chemically modified pieces of RNA called antisense oligonucleotides.

13 Jul 2010

New research shows head size helps measure brain reserve, brain growth

New research shows that people with Alzheimer's disease who have large heads have better memory and thinking skills than those with the disease who have smaller heads, even when they have the same amount of brain cell death due to the disease. The research is published in the July 13, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

13 Jul 2010

Survey shows only few Canadians identify painful physical symptoms of depression

Although the majority of Canadians believe in a mind/body connection, agreeing how they feel physically is related to how they feel emotionally (87 per cent), only half make the link when it comes to depression.

12 Jul 2010

Investment report on Catalyst Pharmaceutical Partners

MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

12 Jul 2010

Sirtuin1 protein promotes memory, brain flexibility: MIT researchers

The same molecular mechanism that increases life span through calorie restriction may help boost memory and brainpower, researchers at MIT's Picower Institute for Learning and Memory report in the July 11 issue of Nature.

12 Jul 2010

USF granted patent for cell transplantation procedure

The University of South Florida's Department of Neurosurgery and Brain Repair has been granted a patent for a cell transplantation procedure combining human umbilical cord blood cells and a sugar-alcohol compound called "mannitol" that may make a big difference in treating life-threatening neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke, among others.

8 Jul 2010

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

Selvita sp. z o.o., from Krakow, Poland and Orion Corporation from Espoo, Finland (ORNBV) today announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita's proprietary program for the treatment of Alzheimer's disease and other cognitive disorders. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.

8 Jul 2010

Studies demonstrate analgesic properties of synthetic cannabinoid

A new compound similar to the active component of marijuana (cannabis) might provide effective pain relief without the mental and physical side effects of cannabis, according to a study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jul 2010

Investment report on Arena Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Arena Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

2 Jul 2010